Manufacturing Deficiencies Delay Decision on Eflapegrastim
Eflapegrastim is a novel, long-acting G-CSF comprised of 2 protein components, an analogue of G-CSF and an Fc antibody fragment.
Oncology
FDA-Approved Biosimilars
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
FDA-Approved Ovarian Cancer Treatments
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
FDA-Approved Breast Cancer Treatments
FDA-approved oral and injectable treatment options for breast cancer.
FDA-Approved Prostate Cancer Treatments
Approved prostate cancer drug treatments including formulations and usual dosing.
Emetogenic Potential of Antineoplastic Agents
Emetogenic potential (high, moderate, low, or minimal risk) of oral and injectable antineoplastic agents.
Antiemetic Treatments
Antiemetic treatment chart including drug formulations, strengths, and usual doses for nausea/vomiting.
- Loading...
Loading...
Loading... 
Loading...